Abstracts tagged "Anxiety"

Abstract Number: 134 • 2020 Pediatric Rheumatology Symposium
Evaluation of Self-report Screening Measures in the Detection of Depressive and Anxiety Disorders Among Children and Adolescents with Systemic Lupus Erythematosus
Michelle Quilter¹, Katherine Cost ², Reva Schachter ³, Julie Couture ⁴, Ashley Danguecan ⁵, Lawrence Ng ⁶, Daniela Dominguez ⁶, Linda Hiraki ⁷, Deborah Levy ⁸, Earl D. Silverman ⁹, Kate Neufeld ¹⁰, Andrea Knight ¹¹ and Daphne Korczak ², ¹Dept. of Psychiatry, Hospital for Sick Children, Dept. of Psychiatry, University of Toronto, Toronto, Ontario, Canada, ²Dept. of Psychiatry, Hospital for Sick Children, Dept. of Psychiatry, University of Toronto, Toronto, Canada, ³Dept. of Psychiatry, Hospital for Sick Children,, Toronto, Canada, ⁴Division of Pediatric Rheumatology-Immunology, CHU Sainte-Justine, Department of Pediatrics, University of Montreal, Montreal, Quebec, Canada, ⁵Hospital for Sick Children, Toronto, Canada, ⁶Division of Rheumatology, The Hospital for Sick Children, Toronto, Canada, ⁷Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children, Department of Pediatrics, University of Toronto, Toronto, Canada, ⁹Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Translational Medicine, Research Institute, The Hospital for Sick Children, Toronto, Canada, ¹⁰University of Toronto, The Hospital for Sick Children, Toronto, Canada, ¹¹SickKids Research Institute, Toronto, Canada
Background/Purpose: Screening for co-morbid psychiatric disorder is of high clinical importance in childhood-onset systemic lupus erythematosus (cSLE). However, there are no validated screening measures for…
Abstract Number: 1341 • 2019 ACR/ARP Annual Meeting
Impact of Tocilizumab on Anxiety and Depression in Patients with Rheumatoid Arthritis
Shmuel Tiosano ¹, Yarden Yavne ¹, Abdulla Watad ², Pnina Langevitz ³, Merav Lidar ⁴, Joy Feld ⁵, Moshe Tishler ⁶, Suhail Aamar ⁷, Ori Elkayam ⁸, Alexandra Balbir-Gurman ⁹, Yair Molad ¹⁰, Sharon Ehrlich ¹¹, Daniela Amital ¹² and Howard AMITAL¹, ¹Department of Medicine B, Ramat-Gan, Israel, ²Department of Medicine “B”, Zabludowicz Center for Autoimmune Diseases Sheba Medical Center, Ramat-Gan, Israel, ³Rhematology Unit, Ramat-Gan, Israel, ⁴Rheumatology Unit Sheba Medical Center, Ramat Gan, Israel, ⁵Carmel Hospital, Haifa, Israel, ⁶5Internal Department B, Assaf Harofeh Medical Center, Zrifin, Israel, Zrifin, Israel, ⁷Rheumatology Unit, Hadassah Mount Scopus Medical Center, Jeursalem, Israel, Jerusalem, Israel, ⁸Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁹Rambam Medical Center, Haifa, Israel, ¹⁰Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petach Tikva, HaMerkaz, Israel, ¹¹Roche Pharmaceuticals (Israel) Ltd., Hod HaSharon, Israel., Hod-Hashaon, Israel, ¹²Ness Ziona Beer-Yaacov Mental Health Center,, Beer-Yaakov, Israel
Background/Purpose: Mood disorders, such as anxiety and depression are extremely prevalent amongst patients with rheumatoid arthritis (RA). In this study we sought to assess the…
Abstract Number: 1444 • 2019 ACR/ARP Annual Meeting
Tofacitinib in Patients with Rheumatoid Arthritis and Indicative of Depression And/or Anxiety: A Post Hoc Analysis of Phase 3 and Phase 3b/4 Clinical Trials
Gustavo Citera¹, Rakesh Jain ², Fedra Irazoque ³, Renato Guzman ⁴, Hugo Madariaga ⁵, David Gruben ⁶, Lisy Wang ⁶, Lori Stockert ⁷, Ming-Ann Hsu ⁸, Karina Santana ⁹, Abbas Ebrahim ¹⁰ and Dario Ponce de Leon ¹¹, ¹Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ²Texas Tech University School of Medicine, Lubbock, TX, ³Hospital Angeles Mocel, San Miguel, Mexico, ⁴Fundación Universitaria Juan N. Corpas e IDEARG, Bogota, Colombia, ⁵Clínica del Sur, Arequipa, Peru, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Collegeville, PA, ⁸Pfizer Inc, Groton, ⁹Pfizer Inc, Mexico City, Mexico, ¹⁰Pfizer Inc, Collegeville, ¹¹Pfizer Inc, Lima, Peru
Background/Purpose: Depression and anxiety are common in patients (pts) with RA1 and can lead to reduced quality of life, functional capacity, and RA treatment response.2-4…
Abstract Number: 1741 • 2019 ACR/ARP Annual Meeting
Depression and Anxiety Symptoms in Childhood-Onset Systemic Lupus Erythematosus
Kate Neufeld¹, Frank Silverio ², Lawrence Ng ³, Ashley Danguecan ⁴, Daniela Dominguez ³, Reva Schachter ², Michelle Quilter ⁵, Julie Couture ⁶, Daphne Korczak ⁷, Deborah Levy ⁸, Linda Hiraki ⁹, Earl D. Silverman ¹⁰ and Andrea Knight ¹¹, ¹Division of Rheumatology, The Hospital For Sick Children, University of Toronto, Toronto, Canada, ²The Hospital for Sick Children, Toronto, Canada, ³Division of Rheumatology, The Hospital for Sick Children, Toronto, Canada, ⁴Division of Rheumatology and Dept of Psychology, The Hospital For Sick Children, Toronto, Canada, ⁵Department of Psychiatry,The Hospital For Sick Children, Toronto, Canada, ⁶The Hospital for Sick Children, Montreal, Canada, ⁷Dept of Psychiatry, SickKids and Dept of Psychiatry, University of Toronto, Toronto, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁹Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, Canada, ¹⁰Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Translational Medicine, Research Institute, The Hospital for Sick Children, Toronto, Canada, ¹¹Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Depression and anxiety disorders are common in patients with childhood-onset systemic lupus erythematosus (cSLE). It is unclear if they are due to central nervous…
Abstract Number: 2398 • 2019 ACR/ARP Annual Meeting
Prevalence of Anxiety and Depression in a Cohort of Patients with Rheumatic Diseases on Biological Infusions
Alexander Peck¹, Ella Starobinska ², Gilbert Ortega ¹, Jaclyn Leong ¹, Travis Maestas ¹, Phan Saligrama ¹, Jawad Bilal ¹ and Dominick Sudano ³, ¹University of Arizona College of Medicine, Tucson, AZ, ²University of Arizona College of Medicine, Tucson, AL, ³Banner University Medical Center Tucson, Tucson
Background/Purpose: Studies have shown an increased prevalence of psychologic disorders in rheumatic diseases, such as rheumatoid arthritis, systemic lupus erythematosus, and psoriatic arthritis, compared to…
Abstract Number: 1129 • 2018 ACR/ARHP Annual Meeting
Prevalence, Incidence, Determinants, and Impacts of Depression and Anxiety in Gout: A Systematic Review
Alyssa Howren^1,2,3, Enav Z. Zusman^1,2,3, Sharan K. Rai^2,4,5, Kam Shojania^2,6 and Mary A. De Vera^1,2,3, ¹Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³Collaboration for Outcomes Research and Evaluation (CORE), Vancouver, BC, Canada, ⁴Program in Population Health Sciences, Graduate School of Arts and Sciences, Harvard University, Boston, MA, ⁵Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁶Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: A previously synthesized positive association between gout and depression has combined studies of both prevalent and incident depression. To disentangle these data and provide…
Abstract Number: 1598 • 2018 ACR/ARHP Annual Meeting
Depression and Anxiety Reduce Probability of Achieving a State of Minimal Disease Activity in Patients with Psoriatic Arthritis
Antonio Wong Lam¹, Justine Y. Ye², Dafna D Gladman¹ and Vinod Chandran², ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Depression and/or anxiety are comorbidities associated with psoriatic arthritis (PsA) that may affect treatment response. We aimed to determine whether the presence of depression/anxiety…
Abstract Number: 1651 • 2018 ACR/ARHP Annual Meeting
Epidemiology of Depression and Anxiety in Patients with Psoriatic Arthritis: A Systematic Review and Meta-Analysis
Enav Z. Zusman^1,2,3, Alyssa Howren^1,2,3, Jan Dutz⁴ and Mary A. De Vera^1,2,3, ¹Collaboration for Outcomes Research and Evaluation (CORE), Vancouver, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ⁴Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Shared inflammatory processes underscore a substantial burden and risk of psychiatric complications – namely depression and anxiety – in patients with psoriatic arthritis (PsA),…
Abstract Number: 1847 • 2018 ACR/ARHP Annual Meeting
Screening Youth with Lupus for Depression and Anxiety in Pediatric Rheumatology Clinics
Tamar Rubinstein¹, Marija Dionizovik-Dimanovski², Chelsey Smith³, Raphael Kraus⁴, Jordan T. Jones⁵, Julia Harris⁶, Martha Rodriguez⁷, Lauren Faust⁸, Beth Rutstein⁸, Rebecca Puplava⁹, Melissa Tesher⁹, Alaina M. Davis¹⁰, Karen Onel¹¹, Sangeeta Sule¹², Emily von Scheven¹³ and Andrea M. Knight¹⁴, ¹Pediatric Rheumatology, Albert Einstein College of Medicine, Children's Hospital at Montefiore, Bronx, NY, ²Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ³Children's Mercy Kansas City, Kansas City, MO, ⁴Children's Hospital at Montefiore, Bronx, NY, ⁵University of Kansas, Kansas City, KS, ⁶Children's Mercy - Kansas City, Kansas City, MO, ⁷Riley Children’s Hospital at Indiana, Indianapolis, IN, ⁸Children's Hospital of Philadelphia, Philadelphia, PA, ⁹University of Chicago Medicine, Chicago, IL, ¹⁰Division of Pediatric Rheumatology, Monroe Carell Junior Children's Hospital at Vanderbilt, Nashville, TN, ¹¹Hospital for Special Surgery, New York, NY, ¹²Pediatrics, Johns Hopkins University, Baltimore, MD, ¹³Pediatric Rheumatology, University of California San Francisco, San Francisco, CA, ¹⁴Center for Pediatric Clinical Effectiveness & PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Despite high rates of depression and anxiety in pediatric lupus, standardized mental health screening is not routinely practiced by pediatric rheumatologists. Our objectives were…
Abstract Number: 1950 • 2018 ACR/ARHP Annual Meeting
Self-Reported Depression and Anxiety Among US Adults Aged 18-44 Years with Arthritis, National Health Interview Survey 2014-2016
Dana Guglielmo¹, Jennifer M. Hootman², Louise Murphy², Michael Boring³, Kristina Theis², Charles G. Helmick², Kamil E. Barbour² and Patricia Katz⁴, ¹Oak Ridge Institute for Science and Education, Oak Ridge, TN, ²Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA, ³Cutting Edge Technology and Solutions, Mesa, AZ, ⁴University of California San Francisco, San Francisco, CA
Background/Purpose: Depression and anxiety are frequent comorbid conditions among adults with arthritis, and are associated with poorer quality of life, reduced adherence and efficacy of…
Abstract Number: 2162 • 2018 ACR/ARHP Annual Meeting
The Prevalence, Incidence, and Determinants of Depression and Anxiety in Less Common Systemic Autoimmune Rheumatic Diseases: A Systematic Review and Meta-Analysis
Alyssa Howren^1,2,3, Enav Z. Zusman^1,2,3, J. Antonio Avina-Zubieta^2,4 and Mary A. De Vera^1,2,3, ¹Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³Collaboration for Outcomes Research and Evaluation (CORE), Vancouver, BC, Canada, ⁴Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Individuals with systemic autoimmune rheumatic diseases (SARDs), including systemic lupus erythematosus (SLE), systemic sclerosis/scleroderma (SSc), Sjogren’s syndrome (SjS), dermatomyositis/polymyositis (DM/PM), and systemic vasculitides (SV),…
Abstract Number: 2393 • 2018 ACR/ARHP Annual Meeting
Is Methotrexate-Induced Nausea in Juvenile Idiopathic Arthritis Influenced By Anxiety or Coping Strategies?
Nini Kyvsgaard¹, Mikael Thastum², Torben Mikkelsen¹, Anne Estmann³ and Troels Herlin¹, ¹Pediatric and Adolescent Medicine, Aarhus University Hospital, Aarhus N, Denmark, ²Department of Psychology and Behavioural Sciences, Aarhus University, Aarhus C, Denmark, ³Department of Pediatric Rheumatology, H.C. Andersen's Children's Hospital, Odense, Denmark
Background/Purpose: Nausea to low-dose methotrexate (MTX) is a significant clinical challenge in the treatment of juvenile idiopathic arthritis (JIA). There exists a large inter-individual variation…
Abstract Number: 194 • 2017 ACR/ARHP Annual Meeting
Kinesiophobia Moderates the Association between Anxiety and Disability in Chronic Low Back Pain
Jenna Goesling¹, Stephanie Moser², Jennifer Pierce¹ and Christian Bolton³, ¹Department of Anesthesiology, University of Michigan, Ann Arbor, MI, ²Anesthesiology, University of Michigan, Ann Arbor, MI, ³University of Michigan, Ann Arbor, MI
Background/Purpose: · Low back pain is a debilitating and costly condition with complex biological, psychological, and social factors contributing to the development of chronic low…
Abstract Number: 314 • 2017 ACR/ARHP Annual Meeting
Effects of Exercise on Anxiety in Adults with Arthritis: A Systematic Review with Meta-Analysis
George Kelley¹, Kristi Kelley¹ and Leigh F. Callahan², ¹Biostatistics, West Virginia University, Morgantown, WV, ²Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Previous randomized controlled trials have led to conflicting findings regarding the effects of exercise on anxiety in adults with arthritis and other rheumatic diseases…
Abstract Number: 607 • 2017 ACR/ARHP Annual Meeting
Secukinumab Treatment of Psoriatic Arthritis and Moderate to Severe Psoriasis Relieves Anxiety/Depression up to 52 Weeks: An Overview from Secukinumab Phase 3 Clinical Trials
Philip J Mease¹, Mark Lebwohl², Isabelle Gilloteau³, Todd Fox³, Jaime Oliver³, Steffen Jugl³ and Alice B Gottlieb⁴, ¹University of Washington School of Medicine and Swedish Medical Center, Seattle, WA, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³Novartis Pharma AG, Basel, Switzerland, ⁴Department of Dermatology, New York Medical College, Vallhalla, NY
Background/Purpose: Secukinumab (SEC), a fully human monoclonal antibody selectively neutralizing interleukin-17A, exhibits significant efficacy, with a favorable safety profile, in the treatment of psoriatic arthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].